Item 2.02 Results of Operations and Financial Condition.
The information set forth in Item 8.01 under the caption “Preliminary Financial Information (Unaudited)” is incorporated into this Item 2.02 by reference.
Item 8.01 Other Events.
Preliminary Financial Information (Unaudited)
Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) reports that it estimates its cash, cash equivalents and marketable securities as of January 2, 2024 were approximately $205.4 million. This estimate of the Company’s cash, cash equivalents and marketable securities as of January 2, 2024 is preliminary, has not been audited, is based on information available to the Company as of the filing of this Current Report on Form 8-K (this “Report”), and is subject to change. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position as of January 2, 2024. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary information and, accordingly, does not express an opinion or any other form of assurance about it.
Corporate Update
The Company is providing a corporate update, attached as Exhibit 99.1 to this Report and incorporated by reference herein.
Cautionary Note Regarding Forward-Looking Statements
This Report, including Exhibit 99.1 attached hereto, contains forward-looking statements, including statements about the Company’s preliminary estimates of cash, cash equivalents and marketable securities as of January 2, 2024, the initial interim clinical data from the ARDENT trial and the Company’s belief that it supports further dose escalation and expansion within the ARDENT trial and broader application of this technology in allogeneic cell therapies in other indications, our beliefs relating to our observations of data from our clinical trials and recently conducted studies as well as expectations regarding additional clinical data to be generated and reported by the Company. These forward-looking statements reflect the Company’s views regarding current expectations and projections about future events and conditions and are based on currently available information. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict, including risks related to preliminary financial results, such as the risks that the preliminary financial information reflects information available to the Company only at this time and may differ from actual results, risks and uncertainties associated with discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as a clinical stage company, including the potential for the Company’s product candidates to cause serious adverse events, the timing, progress and results of the Company’s clinical trials, the potential for any clinical trial results to differ from preclinical, interim, preliminary, topline or expected results, regulatory risks, and the Risk Factors identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on 10-K for the year ended December 31, 2022 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023; therefore, the Company’s actual results could differ materially from those expressed, implied or forecast in any such forward-looking statements. Expressions of future goals and expectations and similar expressions, including “may,” “will,” “should,” “could,” “aims,” “seeks,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “predicts,” “potential,” “targets,” and “continue,” reflecting something other than historical fact are intended to identify forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. However, readers should carefully review the reports and documents the Company files or furnishes from time to time with the SEC, particularly its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
See the Exhibit Index below, which is incorporated by reference herein.
EXHIBIT INDEX
| | |
Exhibit Number | | Description |
| |
| 99.1 | | Corporate Update |
| |
| 104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
